NASDAQ · Biotechnology

Erasca, Inc. (ERAS) Stock

$14.39 +2.49% NASDAQ: ERAS Healthcare

Valuation

MetricValue
Price$14.39
Market Cap$5.03B
P/E Ratio-15.52
P/B Ratio12.68
P/S Ratio0.00
EPS (TTM)$-0.44
52-Week High$24.28
52-Week Low$2.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-80.43%
ROA-66.02%
ROCE-38.03%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.12
Current Ratio9.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-125.0M$-247.0M$-142.0M$-180.0M$-131.0M
Net Profit$-123.0M$-243.0M$-125.0M$-162.0M$-125.0M
EPS$-1.03$-1.99$-0.83$-0.69$-0.44
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$501.0M$515.0M$395.0M$503.0M$396.0M
Total Liabilities$45.0M$103.0M$79.0M$79.0M$71.0M
Cash$360.0M$284.0M$93.0M$68.0M$74.0M
Borrowings$19.0M$55.0M$56.0M$52.0M$47.0M

Latest News

Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns Simply Wall St. · Jul 16, 2026 Erasca Closes $632.5 Million Upsized Common Stock Offering MT Newswires · Jul 15, 2026 Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire · Jul 15, 2026 Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full? Simply Wall St. · Jul 15, 2026 Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers Simply Wall St. · Jul 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-80.0M$-103.0M$-101.0M$-109.0M$-95.0M
Investing Cash Flow$-83.0M$-88.0M$-93.0M$-179.0M$100.0M
Financing Cash Flow$3.0M$3.0M$0$2.0M$0
Net Cash Flow$295.0M$-76.0M$-191.0M$-25.0M$6.0M
Free Cash Flow$-98.0M$-120.0M$-103.0M$-132.0M$-96.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.14
EV / EBITDA-18.01
FCF Yield-1.92%
Quick Ratio8.29
Interest Coverage—
Return 1Y923.13%
Return 3Y532.05%
Return 5Y-31.36%

Ownership

Insiders Held10.66%
Institutions Held93.59%
Institutions Float Held104.75%
Institutional HolderSharesReport Date
Frazier Life Sciences Management, L.P. 24,675,1882026-03-31
T. Rowe Price Investment Management, Inc.21,259,6462026-03-31
Blackrock Inc.20,151,4062026-03-31
Venrock Adviser, LLC16,382,8122026-03-31
RTW Investments LP16,157,1752026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVBPArriVent BioPharma, Inc. $21.00 +9.38% -7.60 $1.04B 0.00%
CRISCuris, Inc. $0.39 -4.59% -0.06 $753285 0.00%
IDYAIDEAYA Biosciences, Inc. $34.71 -3.90% -19.46 $3.35B 0.00%
KURAKura Oncology, Inc. $9.61 -2.54% -3.16 $854.91M 0.00%
NUVBNuvation Bio Inc. $4.57 -2.77% -11.83 $1.60B 0.00%

About Erasca, Inc.

Erasca, Inc. is led by CEO Jonathan E. Lim, employs 103 people, headquartered in San Diego, US, publicly traded since 2021.

Erasca, Inc. (ERAS) stock trades at $14.39 with a market capitalization of $5.03B. The stock is valued at a negative price-to-earnings (P/E) ratio of -15.52, reflecting a net loss over the last twelve months, price-to-book of 12.68, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.10 and $24.28, and currently trades 40.7% below its 52-week high.

On profitability, Erasca, Inc. generates a return on equity (ROE) of -80.43% (negative, reflecting a net loss), return on capital employed of -38.03%.

Erasca, Inc. by the numbers, 2019–2025

Between 2019 and 2025 Erasca, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-125.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-287.0M.

Borrowings rose from $4.0M to $47.0M, cash from operations was $-95.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -40.4% over five years, and was -38.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Erasca, Inc. (ERAS) — frequently asked questions

What is Erasca, Inc. (ERAS) stock price today?

Erasca, Inc. (ERAS) is currently trading at $14.39, up 2.49% today.

What is ERAS P/E ratio?

Erasca, Inc.'s P/E ratio is -15.52. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is ERAS return on equity (ROE)?

Erasca, Inc.'s return on equity (ROE) is -80.43%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Erasca, Inc.'s market cap?

Erasca, Inc. has a market capitalization of $5.03B.

Does ERAS pay a dividend?

Erasca, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does ERAS carry?

Erasca, Inc. has a debt-to-equity ratio of 0.12. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is ERAS's profit margin?

Erasca, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is ERAS in?

Erasca, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is ERAS listed on?

Erasca, Inc. trades on NASDAQ under the ticker ERAS.

What is ERAS's 52-week range?

Over the last year Erasca, Inc. has traded between $2.10 and $24.28.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens ERAS currently matches

On the figures above, Erasca, Inc. passes the filters for 6 of our ready-made screens, among them Low Debt Stocks, Stocks Under $100, Stocks Under $50. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Low Debt StocksStocks Under $100Stocks Under $50Mid Cap StocksDebt to Equity Below 1 StocksHigh Current Ratio Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.